

ODH Therapeutics Site Information Document

Updated: February 14, 2022

Some therapeutics are distributed through HHS for state-coordinated distribution. Additional information on the State-coordinated distribution is available [here](#).

A side-by-side comparison of the therapeutics with administration, authorized uses, cost/payment and product-specific information is available ([link](#)). All sites should review the Health & Human Services Therapeutics Clinical Implementation Guide ([link](#)) for critical information about the administration of these therapeutics.

ODH Contact Information

The ODH Therapeutics Team can be reached at therapeutics@odh.ohio.gov. Please include your site name/COVID-19 PIN for faster support.

Health Partner Ordering Portal (HPOP)

HPOP is used for daily reporting to HHS of therapeutics administered and available/on-hand. It is **not** used by providers to order product. Product **must** be ordered by the jurisdictions in HPOP.

The HPOP Provider Portal Quick Start Guide is available [here](#).

For issues accessing HPOP, logging in, or using the HPOP Portal, please contact the HPOP Help Desk at cars_helpdesk@cdc.gov or (833) 748-1979.

Enrollment Process

Interested facilities may complete a [Therapeutics Enrollment Form](#) to enroll in the therapeutics program. At this time state allocations are being made by the Ohio Department of Health in cooperation with state partners, associations, and clinical zone leadership to ensure equitable distribution. This process is overseen by the Department of Health and Human Services for all states and product is limited at this time.

We continue to add new providers to the program based on provider type, geographic area and product availability.

Once we have enrolled your facility in HPOP, we will ask you to verify shipping information as well as your state license information.

Survey Process

Surveys are sent to pharmacy points of contact, generally on Friday for completion Tuesday by 5 PM. Survey periods may be adjusted based on products available, holidays and other factors.

Product	Survey Frequency
Monoclonal Therapeutics	Weekly
Oral Therapeutics	Bi-Weekly

Product availability is variable, but regardless of the product, these are scarce resources allocated through an HHS apportionment process.

Reporting Requirements

Ohio’s allocation of therapeutics is directly tied to cases, hospitalizations and utilization, the latter two reported through TeleTracking, OHA Submissions and HPOP. Late reports are not included in HHS’s calculations.


Sites may be required to submit different reports while products transition into HPOP. This table, which will change, defines the products, systems and frequency of reports.

Product	Systems	Frequency
Bebtelovimab, Evusheld, Paxlovid, Molnupiravir	HPOP	Daily (every day the site is open)
Sotrovimab*	TeleTracking, OHA Resource Tracker (Hospitals), National Healthcare Safety Network (LTC),	Wednesday by 11:59 PM

* Sotrovimab has been added to TeleTracking/OHA Resource Tracker. Reporting **will remain through these systems (outside of HPOP)** for now, while HHS evaluates reporting measures.


Reporting Requirements

For bam/ete, sotrovimab, REGEN-COV



Reporting required by 11:59 pm each Wednesday

For Evusheld, Paxlovid, molnupiravir



Reporting required by 11:59 pm daily

Sites administering/dispensing USG-purchased COVID-19 therapeutics must provide information on product utilization and stock on hand

OHA Resource Tracker Sites:

You should file your regular Wednesday OHA Resource Tracker submission by Wednesday at 8:30 AM including courses on hand and courses administered in the prior 7-days.

Therapeutic Course Inventory and Usage

Please Note: If you are using OHA to pass through data to the HHS vendor, TeleTracking, this data is required.

	Courses on Hand	Courses Administered Last Week
Therapeutic A (Casirivimab/Imdevimab) [HHS Required]	<input type="text" value="?"/>	<input type="text" value="?"/>
Therapeutic C (Bamlanivimab/ Etesevimab) [HHS Required]	<input type="text" value="?"/>	<input type="text" value="?"/>
Therapeutic D (Sotrovimab) [HHS Required]	<input type="text" value="?"/>	<input type="text" value="?"/>

**HPOP reporting is required every day the site is open,
regardless of if product is administered that day.**

Documentation on updating the therapeutic courses administered and available is here (<https://docs.oracle.com/en/industries/health-sciences/vpop-partner/vpopc/update-therapeutic-courses-administered-and-available-provider-new-topic.html>).

Sites that do not submit data to US Health & Human Services through the above reports may have therapeutic allocations paused while the site resumes reporting. Questions about reporting can be directed to therapeutics@odh.ohio.gov.

Therapeutics Locator

The U.S. Department of Health and Human Services maintains the COVID-19 Therapeutics Locator. Locator data changes with distributions and is preliminary as sites come online and is not real-time. The locator can be found here: <https://covid-19-therapeutics-locator-dhhs.hub.arcgis.com/>

Wastage

All products requiring cold-chain, must maintain cold-chain compliance after receipt from AmerisourceBergen. Sites that repeatedly report wastage or with unaccounted courses may have their allocations paused until mitigation measures can be put in place to prevent additional wastage. These products come at a significant expense and effective product stewardship is needed for all sites.

Report wastage to therapeutics@odh.ohio.gov. A mechanism within HPOP is being developed to address this.

Reference Documents Available

- HPOP Provider Portal Quick Start Guide ([link](#))
- Side-by-Side Overview of Outpatient Therapies Authorized for Treatment of Mild-Moderate COVID-19 ([link](#))
- HHS Therapeutics Clinical Implementation Guide ([link](#)) – Updated 2/15/2022